Researcher
Hans Wildiers
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From1 Oct 2005 → Today
Projects
1 - 10 of 27
- Breast cancer projectFrom1 Jan 2024 → TodayFunding: Other federal public and semi-governmental institutions
- Real-time qPCR platform enhancing research activities within the Laboratory of Experimental Oncology and the Laboratory of Experimental RadiotherapyFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Building a large blood biobank of patients with new breast cancer diagnosis for future researchFrom1 Jan 2022 → 5 Jun 2023Funding: Other federal public and semi-governmental institutions
- UPTIDER (UZ/KU Leuven Program for post-mortem Tissue Donation to Enhance Research), a unique setting to unravel treatment resistance and disease progression in patients with breast cancer.From1 Oct 2021 → TodayFunding: BOF - projects
- The impact of coaching on quality of life of older cancer patientsFrom27 Sep 2021 → 31 Aug 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Streamlined Geriatric and Oncological evaluation based on IC Technology for holistic patient-oriented healthcare management for older multimorbid patientsFrom1 Apr 2021 → TodayFunding: H2020 - Health, demographic change and wellbeing
- Mechanisms involved in metastasis of luminal breast cancerFrom1 Mar 2021 → 28 Feb 2022Funding: Foundations, funds and other with scientific goal
- The MBC biobank collection.From1 Dec 2020 → 31 Oct 2021Funding: Other federal public and semi-governmental institutions
- Risk prediction and modeling of cancer therapy related cardiotoxicityFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Novel biomarkers in the risk stratification, surveillance and treatment of young breast cancer patients and germline carriers of pathogenic variants in TP53.From1 Sep 2020 → 13 Feb 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 473
- Serum methylmalonic acid concentrations at breast cancer diagnosis significantly correlate with clinical frailty(2024)
Authors: Sigrid Hatse, Cindy Kenis, Anke Vandekeere, Yentl Lambrechts, François Richard, Patrick Neven, Ines Nevelsteen, Christine Desmedt, Sarah-Maria Fendt, Hans Wildiers
- Reporting on invasive lobular breast cancer in clinical trials: a systematic review.(2024)
Authors: Karen Van Baelen, Josephine Van Cauwenberge, Beppe Floris, Hans Wildiers, Christine Desmedt
Pages: 23 - A care pathway for older patients with multimorbidity including cancer - Design of the GERONTE pathway.(2024)
Authors: Cindy Kenis, Hans Wildiers
Pages: 101654 - Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial(2024)
Authors: Hans Wildiers
Pages: 532 - 541 - Self-reported electronic symptom monitoring in older patients with multimorbidity treated for cancer: Development of a core dataset based on expert consensus, literature review, and quality of life questionnaires(2024)
Authors: Hans Wildiers, Annemarie Coolbrandt
- Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium(2024)
Authors: Hans Wildiers
Pages: 351 - 363 - Assessing patient-reported outcomes (PROs) and patient-related outcomes in randomized cancer clinical trials for older adults: Results of DATECAN-ELDERLY initiative(2024)
Authors: Hans Wildiers
- Trial watch: chemotherapy-induced immunogenic cell death in oncology(2023)
Authors: Jenny Sprooten, Isaure Vanmeerbeek, Stefan Naulaerts, Lisa Kinget, An Coosemans, Steven De Vleeschouwer, Els Wauters, Sabine Tejpar, Benoit Beuselinck, Sigrid Hatse, et al.
- Treatment response, tumor infiltrating lymphocytes and clinical outcomes in inflammatory breast cancer treated with neoadjuvant systemic therapy.(2023)
Authors: Maxim De Schepper, Ha Linh Nguyen, François Richard, Sophia Leduc, Hans Wildiers, Ines Nevelsteen, Patrick Neven, Beppe Floris, Christine Desmedt
Pages: 186 - 199 - Navigating next-generation HR+ /HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression(2023)
Authors: Patrick Neven, Sileny Han, Yannick Van Herck, Hans Wildiers